Board of Directors

Image: 

Bruce Booth is a Partner in the Life Sciences group and joined Atlas Venture in 2005. He focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. Bruce currently serves on the Boards of Atlas portfolio companies Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has worked closely with portfolio companies ARCA Biopharma (NASD:ABIO), Archemix, NxStage Medical (NASD:NXTM), Prestwick (acquired by Biovail, Sept 2008), Proprius (acquired by Cypress Biosciences, Feb 2008), and Stromedix.

Image: 

Deborah joined SR One in 2005 and leads SR One’s investment activities in Europe. In addition to Bicycle, she is currently a member of the Board of Directors of Protaffin AG and Syntaxin Limited, and is an observer on the board of 7TM Pharma. Deborah was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO on SIX Swiss Exchange, 2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Board of Ablynx (IPO, Euronext Brussels 2007).

Image: 

Kate is a Managing Partner at SVLS with a focus on biotechnology having joined the company in 1991. Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed, RespiVert and current investments including Bicycle, EUSA and Convergence.

Image: 

Greg is a scientific pioneer of protein engineering, and therapeutic monoclonal antibodies, and an inventor and entrepreneur. He invented techniques to both humanize (1986) and, later, to make fully human antibodies for therapeutic uses. His technology is used in over two-thirds of the antibody products on the market, including the humanized antibodies Campath-1H, Herceptin, Avastin, Synagis and the first human antibody (Humira) to be approved by the US FDA.

Image: 

Dave has 21 years experience of R&D management; his past roles include joint worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. He was responsible for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of the company initially to Oxford Molecular and then Millennium Pharmaceuticals. Post this last acquisition Dave was VP of Pharmaceutical Sciences with responsibility for over 230 scientists.

Image: 

John joined Bicycle Therapeutics as CEO on formation of the company, prior to this he was Vice President and Head of Discovery Biology for the GSK Biopharm CEDD in which capacity he established the current GSK monoclonal antibody programme and was responsible for all biology support for biopharm discovery and development programmes from target to proof of concept

Image: 

Anja is a Managing Director at the Novartis Venture Fund in the Basel office. She is active in Switzerland and Europe and also manages a $20m fund in Korea. Anja serves on the board of directors for Nabriva, Heptares, Covagen, Diagnoplex, and Bicycle Therapeutics. Before her appointment to the Novartis Venture Fund she held the position of assistant to the Chairman and CEO of Novartis.

Image: 

Andy Sandham brings over 30 years experience in building biotechnology businesses. He has played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals. He has also served as non-executive chairman of Syntaxin, Novacta Biosystems, non-executive director of Synosia and was a venture partner with Abingworth LLP. Andy is currently also Chairman and CEO of Kymab, non-executive director of NeurAxon and PBL.